Cargando…
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
Peptide human leukocyte antigen (pHLA) targeting therapeutics like T-cell receptor based adoptive cell therapy or bispecific T cell engaging receptor molecules hold great promise for the treatment of cancer. Comprehensive pre-clinical screening of therapeutic candidates is important to ensure patien...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066226/ https://www.ncbi.nlm.nih.gov/pubmed/37002335 http://dx.doi.org/10.1038/s41598-023-32384-z |
_version_ | 1785018249130278912 |
---|---|
author | Krämer, Stefan Moritz, Andreas Stehl, Luca Hutt, Meike Hofmann, Martin Wagner, Claudia Bunk, Sebastian Maurer, Dominik Roth, Günter Wöhrle, Johannes |
author_facet | Krämer, Stefan Moritz, Andreas Stehl, Luca Hutt, Meike Hofmann, Martin Wagner, Claudia Bunk, Sebastian Maurer, Dominik Roth, Günter Wöhrle, Johannes |
author_sort | Krämer, Stefan |
collection | PubMed |
description | Peptide human leukocyte antigen (pHLA) targeting therapeutics like T-cell receptor based adoptive cell therapy or bispecific T cell engaging receptor molecules hold great promise for the treatment of cancer. Comprehensive pre-clinical screening of therapeutic candidates is important to ensure patient safety but is challenging because of the size of the potential off-target space. By combining stabilized peptide-receptive HLA molecules with microarray printing and screening, we have developed an ultra-high-throughput screening platform named ValidaTe that enables large scale evaluation of pHLA-binder interactions. We demonstrate its potential by measuring and analyzing over 30.000 binding curves for a high-affinity T cell Engaging Receptor towards a large pHLA library. Compared to a dataset obtained by conventional bio-layer interferometry measurements, we illustrate that a massively increased throughput (over 650 fold) is obtained by our microarray screening, paving the way for use in pre-clinical safety screening of pHLA-targeting drugs. |
format | Online Article Text |
id | pubmed-10066226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100662262023-04-02 An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions Krämer, Stefan Moritz, Andreas Stehl, Luca Hutt, Meike Hofmann, Martin Wagner, Claudia Bunk, Sebastian Maurer, Dominik Roth, Günter Wöhrle, Johannes Sci Rep Article Peptide human leukocyte antigen (pHLA) targeting therapeutics like T-cell receptor based adoptive cell therapy or bispecific T cell engaging receptor molecules hold great promise for the treatment of cancer. Comprehensive pre-clinical screening of therapeutic candidates is important to ensure patient safety but is challenging because of the size of the potential off-target space. By combining stabilized peptide-receptive HLA molecules with microarray printing and screening, we have developed an ultra-high-throughput screening platform named ValidaTe that enables large scale evaluation of pHLA-binder interactions. We demonstrate its potential by measuring and analyzing over 30.000 binding curves for a high-affinity T cell Engaging Receptor towards a large pHLA library. Compared to a dataset obtained by conventional bio-layer interferometry measurements, we illustrate that a massively increased throughput (over 650 fold) is obtained by our microarray screening, paving the way for use in pre-clinical safety screening of pHLA-targeting drugs. Nature Publishing Group UK 2023-03-31 /pmc/articles/PMC10066226/ /pubmed/37002335 http://dx.doi.org/10.1038/s41598-023-32384-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Krämer, Stefan Moritz, Andreas Stehl, Luca Hutt, Meike Hofmann, Martin Wagner, Claudia Bunk, Sebastian Maurer, Dominik Roth, Günter Wöhrle, Johannes An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions |
title | An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions |
title_full | An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions |
title_fullStr | An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions |
title_full_unstemmed | An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions |
title_short | An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions |
title_sort | ultra-high-throughput screen for the evaluation of peptide hla-binder interactions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066226/ https://www.ncbi.nlm.nih.gov/pubmed/37002335 http://dx.doi.org/10.1038/s41598-023-32384-z |
work_keys_str_mv | AT kramerstefan anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT moritzandreas anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT stehlluca anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT huttmeike anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT hofmannmartin anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT wagnerclaudia anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT bunksebastian anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT maurerdominik anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT rothgunter anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT wohrlejohannes anultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT kramerstefan ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT moritzandreas ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT stehlluca ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT huttmeike ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT hofmannmartin ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT wagnerclaudia ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT bunksebastian ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT maurerdominik ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT rothgunter ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions AT wohrlejohannes ultrahighthroughputscreenfortheevaluationofpeptidehlabinderinteractions |